TY - JOUR
T1 - Transcription Strikes Back
T2 - Clinical Utility of Lung Adenocarcinoma Subtypes
AU - Skoulidis, Ferdinandos
N1 - Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2021/2/15
Y1 - 2021/2/15
N2 - Using transcriptional profiling, three robust subtypes of nonsquamous non–small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK1/2 inhibitors was reported and an interaction between the mucinous subtype, STK11/LKB1 genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.
AB - Using transcriptional profiling, three robust subtypes of nonsquamous non–small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK1/2 inhibitors was reported and an interaction between the mucinous subtype, STK11/LKB1 genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.
UR - http://www.scopus.com/inward/record.url?scp=85101779501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101779501&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-3914
DO - 10.1158/1078-0432.CCR-20-3914
M3 - Article
C2 - 33328344
AN - SCOPUS:85101779501
SN - 1078-0432
VL - 27
SP - 913
EP - 915
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -